Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

This publication has 24 references indexed in Scilit:

• Multiple myeloma
  Nature Reviews Disease Primers, 2017
• Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
  The Lancet, 2017
• Comparison of Propensity Score Methods and Covariate Adjustment
  JACC, 2017
• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
  The Lancet Oncology, 2016
• VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
  Blood, 2016
• Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
  Statistics in Medicine, 2015
• International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
  Journal of Clinical Oncology, 2014
• A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
  Blood, 2012
• Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples
  Statistics in Medicine, 2009
• A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
  Journal of Chronic Diseases, 1987